Inhibiting a protease could improve the treatment of inflammatory bowel disease

December 03, 2019

Scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) and the Centro de Investigaciones Biológicas (CIB) of the Consejo Superior de Investigaciones Científicas (CSIC) have identified the protease MT1-MMP as a possible future target for drugs to treat inflammatory bowel disease (IBD). The study was led by Dr Alicia G Arroyo and is published today in EMBO Molecular Medicine. The study shows that inhibition of this protease could improve the treatment of IBD.

IBD refers to a group of chronic inflammatory disorders that fall into 2 categories: Crohn disease and ulcerative colitis. Complications associated with these diseases affect the gut (intestinal obstruction, nutrient deficiency, etc.) and other organs (disorders of the skin, joints, eyes, liver and gallbladder, etc.). The appearance of symptoms is unpredictable, and the disease is characterized by periods of remission and relapse. In many patients, symptoms are severe enough to require hospitalization and surgical intervention. Unfortunately, there is currently no universally effective cure for IBD.

During colitis, the intestinal blood vessels duplicate through mechanisms that are poorly understood. In the new study, Dr Arroyo's team used microscopy techniques and 3D image analysis to characterize these duplication events in a mouse model of colitis. These tools enabled the scientists to demonstrate that MT1-MMP expressed on endothelial cells lining the blood vessels impedes their duplication in the inflamed gut, reducing the severity of colitis.

The researchers also investigated the mechanisms underlying vascular duplication during IBD. The first stage in vessel duplication is dilation. One of the most potent vasodilator molecules is nitric oxide, and the authors found that the catalytic activity of MT1-MMP is necessary for nitric oxide production.

To investigate the effect of MT1-MMP on vessel duplication in vivo, the scientists examined the blood vessels supplying the cremaster muscle (covering the testicles and spermatic cord). These vessels are accessible to analysis by intravital microscopy. Using this technique, CNIC researcher Cristina Rius found that the cremaster vessels of mice lacking MT1-MMP did not fully dilate in response to treatment with vasodilators. Similar results were found in blood vessels supplying the intestine.

The authors also found that MT1-MMP 'cuts' the protein thrombospondin-1 (TSP1), generating a TSP1 fragment that binds to the cell adhesion receptor integrin αvβ3. The resulting integrin activation triggers the production of nitric oxide, leading to vasodilation and vessel duplication.

This finding has potential clinical implications. "The study shows that patients with mild IBD have higher than normal circulating levels of TSP1, which could be a useful biomarker of the disease," commented Arroyo.

In addition, first author Sergio Esteban described how the team had managed to "reduce vessel duplication in mice with colitis by administering either an antibody that inhibits MT1-MMP protease action or a TSP1 peptide that blocks TSP1-αvβ3 binding. This result establishes the MT1-MMP-TSP1-αvβ3 integrin pathway as a new therapeutic target, particularly for less severe forms of IBD."

Finally, the team worked with Fernando Martínez of the CNIC Bioinformatics Unit on a computer model to predict MT1-MMP cleavage sites in TSP1. This model will be used to screen for molecules able to block TSP1 cleavage.

Arroyo concluded that "the study presents a new opportunity to develop personalized treatments not only for patients with IBD, but also for patients with other diseases that progress through vessel duplication, like cancer."
Collaborators in this study include Dr Vicente Andrés' group and the Bioinformatics Unit at the CNIC; Dr Javier P. Gisbert--who provided IBD patient samples--and Dr Ana Urzainqui of the Instituto de Investigación Sanitaria-Princesa; and Professor Motoharu Seiki of the University of Tokyo, whose team generated the MT1-MMP reporter mice.

The researchers belong to research networks for cardiovascular disease (CIBER-CV) and liver and digestive diseases (CIBER-EHD) of the Instituto de Salud Carlos III (ISCIII

About the CNIC

The Centro Nacional de Investigaciones Cardiovasculares (CNIC), directed by Dr. Valentín Fuster, is dedicated to cardiovascular research and the translation of knowledge gained into real benefits for patients. The CNIC, recognized by the Spanish government as a Severo Ochoa center of excellence, is financed through a pioneering public-private partnership between the government (through the Carlos III Institute of Health) and the Pro-CNIC Foundation, which brings together 12 of the most important Spanish private companies.

Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.)

Related Colitis Articles from Brightsurf:

High-sugar diet can damage the gut, intensifying risk for colitis
DALLAS - Oct. 28, 2020 - Mice fed diets high in sugar developed worse colitis, a type of inflammatory bowel disease (IBD), and researchers examining their large intestines found more of the bacteria that can damage the gut's protective mucus layer.

Researchers identify enzyme linked to colitis
An enzyme that usually stops bacterial growth in the large intestine stimulates inflammation in some people, resulting in ulcerative colitis - a chronic digestive disease.

Study shows CRISPR effectiveness against colitis pathogen
Research at North Carolina State University shows that the CRISPR-Cas system can be used to effectively target and eliminate specific gut bacteria, in this case Clostridioides difficile, the pathogen that causes colitis -- a chronic, degenerative disease of the colon.

Using artificial intelligence to assess ulcerative colitis
Researchers from Tokyo Medical and Dental University (TMDU) have developed an artificial intelligence system with a deep neural network that can effectively evaluate endoscopic data from patients with ulcerative colitis, which is a type of inflammatory bowel disease, without the need for biopsy collection.

Stanford scientists link ulcerative colitis to missing gut microbes
About 1 million people in the United States have ulcerative colitis, a serious disease of the colon that has no cure and whose cause is obscure.

New AGA guideline outlines treatment best practices for ulcerative colitis patients
An increasing number of drugs are available for long-term management of moderate to severe UC, leading to questions about treatment strategies for optimal patient care.

Colorectal cancer risk remains despite modern treatment for ulcerative colitis
Patients with the inflammatory bowel disease ulcerative colitis have a higher risk of dying from colorectal cancer, despite modern therapy, even though the risk has declined in recent years.

Drug decreases gut leakiness associated with ulcerative colitis
A research team led by biomedical scientists at the University of California, Riverside, has found that a drug approved by the FDA to treat rheumatoid arthritis and ulcerative colitis can repair permeability defects in the gut's epithelium.

Scientists are developing a way to counter ulcerative colitis
Ulcerative colitis (UC) is a long-term condition that results in inflammation and ulcers of the colon and rectum.

Walnuts show protection against ulcerative colitis in early study
Through their complex array of natural compounds and phytochemicals, walnuts provide a multitude of health benefits.

Read More: Colitis News and Colitis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to